$33.63 -$0.87 (-2.5%)

04:30 PM EDT on 07/09/20

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

CAPS Rating: 3 out of 5

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs.

Current Price $33.63 Mkt Cap $4.0B
Open $34.66 P/E Ratio 0.00
Prev. Close $34.50 Div. (Yield) $0.00 (0.0%)
Daily Range $33.25 - $34.82 Volume 720,170
52-Wk Range $9.51 - $39.88 Avg. Daily Vol. 1,297,018

Caps

How do you think NASDAQ:MNTA will perform against the market?

Add Stock to CAPS Watchlist

All Players

406 Outperform
28 Underperform
 

All-Star Players

92 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:MNTA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Kanga88 (38.55)
Submitted February 25, 2014

The business proposition and execution of Momenta has been solid, and it is a matter of time that the company will emerge as an innovative leader in the 21st century pharmaceutical industry. Born in the biotech labs of MIT, MNTA has been developing… More

rknapton (< 20)
Submitted August 22, 2013

Short. Pharma company whose revenues are getting slaughtered.

NASDAQ:MNTA VS S&P 500 (SPY)

Fools bullish on NASDAQ:MNTA are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about MNTA.

Recs

0
Member Avatar Paco57 (62.35) Submitted: 1/14/2020 9:32:05 PM : Outperform Start Price: $20.61 NASDAQ:MNTA Score: +67.18

flying under the radar

Recs

0
Member Avatar AsianMatter (< 20) Submitted: 4/2/2014 9:17:58 PM : Outperform Start Price: $11.52 NASDAQ:MNTA Score: +125.82

IZ

Recs

1
Member Avatar Kanga88 (38.55) Submitted: 2/25/2014 12:38:51 PM : Outperform Start Price: $17.51 NASDAQ:MNTA Score: +22.22

The business proposition and execution of Momenta has been solid, and it is a matter of time that the company will emerge as an innovative leader in the 21st century pharmaceutical industry. Born in the biotech labs of MIT, MNTA has been developing and accumulating advanced proprietary technology which allows it to produce generic drugs cheaper and hopefully purer than the originals. This will allow it to play leadership roles in the US where costs of medicine should account for 10% or so of the running away health costs!
As a bonus, it also has invested in R&D platforms for discovering new drugs, hopefully with breakthroughs in the future too.

Its path to successful commercializations has been full of obstacles, including legal challenges and competitive pressures. But only patient long term investors should invest in biotech stocks-- Caveat emptor !

Leaderboard

Find the members with the highest scoring picks in MNTA.

Score Leader

subodhgupta

subodhgupta (< 20) Score: +442.89

The Score Leader is the player with the highest score across all their picks in MNTA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
subodhgupta < 20 11/9/2007 Outperform 5Y $5.04 +567.26% +124.37% +442.89 0 Comment
coolebo 89.99 11/9/2007 11/6/2010 Outperform 3Y $5.24 +541.79% +125.28% +416.51 0 Comment
rcocoma 57.08 11/9/2007 Outperform 3W $5.30 +535.13% +123.87% +411.26 0 Comment
ripcord114 83.48 12/3/2007 Outperform NS $5.30 +534.53% +123.28% +411.24 0 Comment
FrankCast1e 57.72 11/20/2007 Outperform 5Y $5.31 +533.33% +128.58% +404.75 0 Comment
baller89 97.85 11/28/2007 8/30/2018 Outperform 5Y $5.32 +532.14% +128.33% +403.82 0 Comment
GilB4u 92.79 11/16/2007 Outperform 1Y $5.36 +527.43% +125.02% +402.41 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. ChiouMoney < 20 12/3/2007 Outperform 5Y $5.43 +519.34% +122.15% +397.18 0 Comment
nik2073 29.51 11/12/2007 Outperform NS $5.50 +511.45% +126.72% +384.74 0 Comment
Gegie < 20 11/12/2007 Outperform 1Y $5.50 +511.45% +126.72% +384.74 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MNTA.